TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in numbers of M. pneumoniae-specific INF-γ-secreting T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Clinical Laboratory Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Anti-Drug Antibody (ADA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Superior vertebral body translation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disc space height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rebleeding within 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Risk of severe asthma exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: frequency of vasomotor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject Satisfaction With Breast Implants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Investigator Satisfaction With Breast Implants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Local Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the curve (AUC) of (non) nutrients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change From Baseline in Total Tic Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Proportion of Perfused Vessels (PPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Syndecan-1 serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality rate in sepsis patients
Endpoint domain: Mortality/survival
Primary endpoint: Visual Analogue Scale (VAS) on movement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lowering Hemoglobin A1c (Hb A1c) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time before recovery of hunger
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of HPV test positive women with Pap test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability of Arm, Shoulder and Hand score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Activity of Daily Life recovery time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Nasal inflammatory markers post allergen challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection of early synchronous second primary esophageal carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement of NNRTI/PI associated toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of study participants achieving PMBC viral culture negative status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Inhaler adherence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGF2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rates of CIN2+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of subjects achieving an ACR20 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End Tidal Oxygen Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic improvement by Total Symptom Score (TSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with nasal hyperreactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Missing data rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in cervical HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in cervical/vulvovaginal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of ASIL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Decreased serum cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Increased serum serotonin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Decreased degree scores of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Freedom from distant metastases
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of subjects experiencing CDI recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Circulating Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of type 2 innate lymphoid cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Patients Who Became Nauseated
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients enrolled in clinical intervention trials
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Intravaginal Ejaculatory Latency Time (IELT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient-Reported Outcomes (PRO)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in NIHSS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients willing to use the in-home telemonitoring device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Success of data transmission
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in 10 Meter Walk Test-Self Selected Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comprehensive Complication Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion rates after primary immunization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient Response to Subjective Anxiety Surveys
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blood concentration of galactose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete Heartburn Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage reduction in facial redness and telangiectasias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Event Rate Per 100 Participant-years for Hospitalized Virologically-Confirmed Dengue (VCD) Cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Hospitalized VCD Cases Due to Any and Each Serotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Clinically Severe Hospitalized VCD Cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Neck Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pericranial Muscle Tenderness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Hardness measured by ultrasound elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Functional Linguistic Communication Inventory (FLCI)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: improvement in the degree of non-alcoholic fatty liver disease score (NAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mental Health Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Presence of dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Dermatology Life Quality Index (DLQI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Hyperhidrosis Disease Severity Scale (HDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Pain/Discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Thrombin quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hemoglobin measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: fMRI stability measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurotransmitter production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: QTc at individual Day 7 post-dose Tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Day 7 QTc increase from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average Day 7 QTc observed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite of Revascularization, Re-hospitalization, and Recurrent Cardiac Testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Depressive Symptoms from Baseline to 1-month Followup
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Histopathological diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Presence or absence of circulating tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum protein markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Early onset cardiomyopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of escalating doses of betahistine
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of reported adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Knee Injury and Osteoarthritis Score (KOOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Adductory knee force during stair climbing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 30 day survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Change of resilience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Residual secretion of cortisol and aldosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Relative steady-state bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in seizure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Amount of sedation used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Pain at 2 Hours Post-dose
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Freedom From Most Bothersome Symptoms (MBS) at 2 Hours Post-dose
Endpoint domain: Life impact
Endpoint subdomain: General outcomes
Primary endpoint: Gross Motor Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the left ventricular longitudinal strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hospital admissions with malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Self-reported exposure to secondhand smoke (SHS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of Prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of device and procedure related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Responders with at Least a 30% Reduction in ICSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Candida Culture Free
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma miRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: randomization rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants Awakening or Returning to a Normal Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper limb functional measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower limb functional measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMG and force voluntary output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of SARS-CoV-2 infection
Endpoint domain: Adverse events/effects
Primary endpoint: MDP scores during hospital stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Muscular Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Visual Acuity (ETDRS Letters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progress-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Number and types of mutations in the primary tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number and type of mutations detectable in the matched circulating tumor cell samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: QRS duration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement or healing of clinical signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolution of clinical signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of cardiac output measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in MPO Specific Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NETs level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Uncorrected Visual Acuity (UCVA) at distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum nectin-4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child's impact of mental health problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in total score on the Montgomery-Asberg Depression Rating Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: outcome
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Frequency of implementation of the SOPP checklist
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Numeric Pain Rating Scale for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first adjudicated PH clinical worsening event
Endpoint domain: Mortality/survival
Primary endpoint: Change in plaque index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Change in gingival index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: trunk position tracking accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trunk force tracking accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trunk position stabilization accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trunk force stabilization accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: push stabilization accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pull stabilization accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to progression of disease
Endpoint domain: Mortality/survival
Primary endpoint: Recommended phase II dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cosmetic wound appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional outcome at 3 months after stroke onset
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Curcumin AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Curcumin Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Curcumin Tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probing of depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary success rate of percutaneous ablation treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Adverse Events Reported
Endpoint domain: Adverse events/effects
Primary endpoint: Participant Global Tolerability Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: serum S100B protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Humoral Immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Placental BOLD effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of size measurement accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of eligible participant identification
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of adverse events related to the active study medication
Endpoint domain: Adverse events/effects
Primary endpoint: Bang's Blinding Index (likelihood of unblinding)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Monitoring study medication compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tolerability of the PolyEnv1 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of the PolyEnv1 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: plasma LDL-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time interval from induction to vaginal birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (AUClast) of LCQ908
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time profile from time zero extrapolated to infinite time [AUC(0-inf)] of LCQ908
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of LCQ908
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Planned dose on time (PDOT) application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Percentage Change in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of serious adverse events (SAEs) related to study product
Endpoint domain: Adverse events/effects
Primary endpoint: Number of solicited local adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of solicited systemic adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first postoperative analgesic dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute pain at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Physical Performance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional score of the QLQ-C30 quality of life questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Angiographic late loss at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BOO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DU
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Upper limb Fugl Meyer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under ROC curve (AUROC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Contrast-Induced Acute Kidney Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Complete enteroscopy achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Seroprotected Subjects Against Poliovirus Types 1, 2 and 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes